[go: up one dir, main page]

NZ602808A - Angiogenesis using placental stem cells - Google Patents

Angiogenesis using placental stem cells

Info

Publication number
NZ602808A
NZ602808A NZ602808A NZ60280811A NZ602808A NZ 602808 A NZ602808 A NZ 602808A NZ 602808 A NZ602808 A NZ 602808A NZ 60280811 A NZ60280811 A NZ 60280811A NZ 602808 A NZ602808 A NZ 602808A
Authority
NZ
New Zealand
Prior art keywords
stem cells
placental stem
angiogenesis
treating
disruption
Prior art date
Application number
NZ602808A
Inventor
Aleksandr Kaplunovsky
Eric Law
Aleksander Francki
Jia-Lun Wang
Stewart Abbot
Jennifer Paredes
Kristen Labazzo
Vladimir Jankovic
James Edinger
Neerav Padliya
Robert J Hariri
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44761079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ602808(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Priority to NZ630009A priority Critical patent/NZ630009A/en
Publication of NZ602808A publication Critical patent/NZ602808A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3633—Extracellular matrix [ECM]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3808—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)

Abstract

Disclosed is the use of CD10+, CD34–, CD105+, CD200+ placental stem cells in the manufacture of a medicament for treating an individual having a disease or disorder of the circulatory system, wherein said treating results in a detectable improvement of one or more symptoms of said disease or disorder. Further disclosed is the use of CD10+, CD34–, CD105+, CD200+ placental stem cells in the manufacture of a medicament for treating an individual having a disruption of blood flow in or around a limb, wherein said treating results in a detectable improvement of one or more symptoms caused by said disruption of blood flow.
NZ602808A 2010-04-07 2011-04-06 Angiogenesis using placental stem cells NZ602808A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ630009A NZ630009A (en) 2010-04-07 2011-04-06 Angiogenesis using placental stem cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32182210P 2010-04-07 2010-04-07
PCT/US2011/031335 WO2011127117A1 (en) 2010-04-07 2011-04-06 Angiogenesis using placental stem cells

Publications (1)

Publication Number Publication Date
NZ602808A true NZ602808A (en) 2014-10-31

Family

ID=44761079

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ602808A NZ602808A (en) 2010-04-07 2011-04-06 Angiogenesis using placental stem cells
NZ630009A NZ630009A (en) 2010-04-07 2011-04-06 Angiogenesis using placental stem cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ630009A NZ630009A (en) 2010-04-07 2011-04-06 Angiogenesis using placental stem cells

Country Status (25)

Country Link
US (3) US9254302B2 (en)
EP (2) EP2556145B1 (en)
JP (5) JP6097684B2 (en)
KR (7) KR20190076060A (en)
CN (2) CN102933703A (en)
AR (2) AR081166A1 (en)
AU (1) AU2011237747B2 (en)
CA (1) CA2795518C (en)
CY (1) CY1118105T1 (en)
DK (2) DK2556145T3 (en)
ES (1) ES2602474T3 (en)
HR (1) HRP20161350T1 (en)
HU (1) HUE029144T2 (en)
IL (2) IL250234B2 (en)
LT (1) LT2556145T (en)
MX (3) MX347451B (en)
NZ (2) NZ602808A (en)
PL (1) PL2556145T3 (en)
PT (1) PT2556145T (en)
RS (1) RS55287B1 (en)
SI (1) SI2556145T1 (en)
SM (1) SMT201600377B (en)
TW (5) TWI578993B (en)
WO (1) WO2011127117A1 (en)
ZA (1) ZA201606733B (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2522890T3 (en) 2000-12-06 2014-11-19 Anthrogenesis Corporation Method to collect placental stem cells
EP3246396B1 (en) 2001-02-14 2020-01-29 Celularity, Inc. Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US9119899B2 (en) * 2006-01-18 2015-09-01 Cormatrix Cardiovascular, Inc. Method and system for treatment of cardiovascular disorders
ES2452595T3 (en) 2005-10-13 2014-04-02 Anthrogenesis Corporation Immunomodulation using placental stem cells
ES2549111T3 (en) 2005-12-29 2015-10-23 Anthrogenesis Corporation Placental stem cell populations
WO2008100497A1 (en) 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
CN101878034B (en) 2007-09-28 2013-11-20 细胞基因细胞疗法公司 Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
ES2612469T3 (en) 2008-08-20 2017-05-17 Anthrogenesis Corporation Improved cell composition and methods of making it
CA2734446C (en) 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
MX353489B (en) 2009-07-02 2018-01-16 Anthrogenesis Corp Method of producing erythrocytes without feeder cells.
WO2011094181A1 (en) 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
LT2556145T (en) 2010-04-07 2016-11-10 Anthrogenesis Corporation Angiogenesis using placental stem cells
KR20130092394A (en) 2010-04-08 2013-08-20 안트로제네시스 코포레이션 Treatment of sarcoidosis using placental stem cells
JP5996533B2 (en) 2010-07-13 2016-09-21 アントフロゲネシス コーポレーション How to generate natural killer cells
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
US20120264215A1 (en) * 2011-04-18 2012-10-18 Korea University Research And Business Foudation Of Korea University Placenta-derived cell-conditioned culture media and animal-free, feeder-free method for culturing stem cells using the same
WO2012166844A2 (en) 2011-06-01 2012-12-06 Anthrogenesis Corporation Treatment of pain using placental stem cells
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
WO2013082417A1 (en) * 2011-11-30 2013-06-06 Anthrogenesis Corporation Treatment using placental stem cells
EP2833896A2 (en) * 2012-03-30 2015-02-11 University Of Southern California Compositions and treatment methods for mesenchymal stem cell-induced immunoregulation
EP2830639B1 (en) * 2012-03-30 2019-05-08 University of Central Florida Research Foundation, Inc. Methods and compositions using fgf-8 to enhance cardiac regeneration and attenuate adverse cardiac remodeling
US9943551B2 (en) 2012-08-15 2018-04-17 Mimedx Group, Inc. Tissue grafts composed of micronized placental tissue and methods of making and using the same
US9180145B2 (en) 2012-10-12 2015-11-10 Mimedx Group, Inc. Compositions and methods for recruiting and localizing stem cells
WO2014093753A1 (en) 2012-12-14 2014-06-19 Anthrogenesis Corporation Anoikis resistant placental stem cells and uses thereof
US10111910B2 (en) 2013-01-18 2018-10-30 Mimedx Group, Inc. Methods for treating cardiac conditions
US10206977B1 (en) 2013-01-18 2019-02-19 Mimedx Group, Inc. Isolated placental stem cell recruiting factors
JP2016506968A (en) 2013-02-05 2016-03-07 アントフロゲネシス コーポレーション Placenta-derived natural killer cells
EP3882336A1 (en) 2013-03-14 2021-09-22 Celularity Inc. Enhanced placental stem cells and uses thereof
PT2968420T (en) * 2013-03-14 2019-01-11 Celularity Inc Use of placental stem cells in treatment of acute kidney injury
US10029030B2 (en) 2013-03-15 2018-07-24 Mimedx Group, Inc. Molded placental tissue compositions and methods of making and using the same
EP3068432A4 (en) 2013-11-15 2017-04-19 Anthrogenesis Corporation Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses
WO2015109329A1 (en) * 2014-01-17 2015-07-23 Mimedx Group, Inc. Method for inducing angiogenesis
CN103756957B (en) * 2014-01-27 2015-11-18 山东省齐鲁干细胞工程有限公司 A kind of method of wash-out endothelial progenitor cells from placenta
EP3102031B1 (en) * 2014-02-05 2022-01-19 Muffin Incorporated Compartmented cryopreservation container and uses thereof
JP6474549B2 (en) * 2014-03-03 2019-02-27 国立大学法人徳島大学 Evaluation index of stem cell culture product and its use
WO2016011283A1 (en) * 2014-07-17 2016-01-21 Cedars-Sinai Medical Center Blood-vessel therapeutic patch composed of endothelial cells derived from ipscs pre-treated with leptin
US20170290861A1 (en) * 2014-09-26 2017-10-12 Anthrogenesis Corporation Treatment of diabetic foot ulcer using placental stem cells
CN107106615A (en) * 2014-10-09 2017-08-29 人类起源公司 Adherent cell exosomes derived from placenta and uses thereof
EP3214171A4 (en) * 2014-10-29 2018-07-11 Sungkwang Medical Foundation Placenta-derived cells excreting c3 or c1r complement and composition containing same
KR20170102319A (en) * 2014-12-31 2017-09-08 안트로제네시스 코포레이션 Methods for isolation of platelets
MX2017015147A (en) * 2015-05-26 2018-03-28 Celularity Inc Angiogenesis using stimulated placental stem cells.
KR102011634B1 (en) * 2015-08-28 2019-08-19 주식회사 차바이오텍 Enhanced postnatal adherent cells and use thereof
WO2017048741A1 (en) * 2015-09-15 2017-03-23 Anthrogenesis Corporation Treatment of diabetic peripheral neuropathy using placental cells
EP3356515B1 (en) * 2015-09-29 2024-06-05 Celularity Inc. Cell potency assay
CN106310227A (en) * 2016-09-30 2017-01-11 广州赛莱拉干细胞科技股份有限公司 Stem cell preparation as well as preparation method and application thereof
WO2019177269A1 (en) * 2018-03-16 2019-09-19 주식회사 메디노 Angiogenesis-inducing method using neural stem cell
CN108904799A (en) * 2018-07-09 2018-11-30 夏荣木 A kind of anti-tumor agent and the method for preparation
KR102593791B1 (en) * 2021-02-26 2023-10-25 경희대학교 산학협력단 Method for producing endothelial progenitor cells derived from bone marrow with improved vascularization using PDGF-BB and method for producing cell therapy products for treating vascular insufficiency-related diseases
CN116334210B (en) * 2023-03-06 2025-10-31 中国人民解放军总医院 Application of ALDH1A1 and AMIGO2 genes in preparation of atrial fibrillation diagnosis and intervention products

Family Cites Families (272)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862002A (en) 1962-05-08 1975-01-21 Sanfar Lab Inc Production of physiologically active placental substances
US4829000A (en) 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5266480A (en) 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
US5902741A (en) 1986-04-18 1999-05-11 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures
US5863531A (en) 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
NZ226750A (en) 1987-10-29 1990-09-26 Amrad Corp Ltd Immortalisation of neural precursor cells by introducing a retrovirus vector containing a myc-oncogene
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5192553A (en) 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
GB8803697D0 (en) 1988-02-17 1988-03-16 Deltanine Research Ltd Clinical developments using amniotic membrane cells
US5284766A (en) 1989-02-10 1994-02-08 Kao Corporation Bed material for cell culture
FR2646438B1 (en) 1989-03-20 2007-11-02 Pasteur Institut A METHOD FOR SPECIFIC REPLACEMENT OF A COPY OF A GENE PRESENT IN THE RECEIVER GENOME BY INTEGRATION OF A GENE DIFFERENT FROM THAT OR INTEGRATION
US5635386A (en) 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
US5605822A (en) 1989-06-15 1997-02-25 The Regents Of The University Of Michigan Methods, compositions and devices for growing human hematopoietic cells
US5763266A (en) 1989-06-15 1998-06-09 The Regents Of The University Of Michigan Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells
US5437994A (en) 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
EP0950707B1 (en) 1989-07-25 2009-02-18 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
SG122763A1 (en) 1989-11-06 2006-06-29 Cell Genesys Inc Production of proteins using homologous recombination
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US6326198B1 (en) 1990-06-14 2001-12-04 Regents Of The University Of Michigan Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5226914A (en) 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US6010696A (en) 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5733542A (en) 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5744361A (en) 1991-04-09 1998-04-28 Indiana University Expansion of human hematopoietic progenitor cells in a liquid medium
WO1993003139A1 (en) 1991-08-08 1993-02-18 Kao Corporation Cell culture support, production thereof, and production of cell cluster using same
EP0529751A1 (en) 1991-08-09 1993-03-03 W.R. Grace & Co.-Conn. Cell culture substrate, test material for cell culture and preparations thereof
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
AU679436B2 (en) 1991-12-23 1997-07-03 British Bio-Technology Limited Stem cell inhibiting proteins
EP0590156A4 (en) 1992-03-31 1994-07-13 Toray Industries Novel, physiologically active protein and hemopoietic stem cell growth promoter
US5552267A (en) 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
WO1994000484A1 (en) 1992-06-22 1994-01-06 Young Henry E Scar inhibitory factor and use thereof
US5693482A (en) 1992-07-27 1997-12-02 California Institute Of Technology Neural chest stem cell assay
US5672346A (en) 1992-07-27 1997-09-30 Indiana University Foundation Human stem cell compositions and methods
US5849553A (en) 1992-07-27 1998-12-15 California Institute Of Technology Mammalian multipotent neural stem cells
WO1994011493A1 (en) 1992-11-16 1994-05-26 Applied Immune Sciences, Inc. Pluripotential quiescent stem cell population
US5772992A (en) 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
ES2185649T3 (en) 1993-03-31 2003-05-01 Wellstat Therapeutics Corp INHIBITORS OF THE PROLIFERATION OF GERMINAL CELLS AND THEIR USES.
GB9308271D0 (en) 1993-04-21 1993-06-02 Univ Edinburgh Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
US5709854A (en) 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US6001654A (en) 1994-01-28 1999-12-14 California Institute Of Technology Methods for differentiating neural stem cells to neurons or smooth muscle cells using TGT-β super family growth factors
US5942496A (en) 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US6174333B1 (en) 1994-06-06 2001-01-16 Osiris Therapeutics, Inc. Biomatrix for soft tissue regeneration using mesenchymal stem cells
JPH10505250A (en) 1994-06-06 1998-05-26 ケース ウエスターン リザーブ ユニバーシティ Biomatrix for tissue regeneration
DE4422667A1 (en) 1994-06-30 1996-01-04 Boehringer Ingelheim Int Process for the production and cultivation of hematopoietic progenitor cells
US6103522A (en) 1994-07-20 2000-08-15 Fred Hutchinson Cancer Research Center Human marrow stromal cell lines which sustain hematopoiesis
US5516532A (en) 1994-08-05 1996-05-14 Children's Medical Center Corporation Injectable non-immunogenic cartilage and bone preparation
US5827742A (en) 1994-09-01 1998-10-27 Beth Israel Deaconess Medical Center, Inc. Method of selecting pluripotent hematopioetic progenitor cells
US5665557A (en) 1994-11-14 1997-09-09 Systemix, Inc. Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5789147A (en) 1994-12-05 1998-08-04 New York Blood Center, Inc. Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5695998A (en) 1995-02-10 1997-12-09 Purdue Research Foundation Submucosa as a growth substrate for islet cells
US6011000A (en) 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US5906934A (en) 1995-03-14 1999-05-25 Morphogen Pharmaceuticals, Inc. Mesenchymal stem cells for cartilage repair
US5716616A (en) 1995-03-28 1998-02-10 Thomas Jefferson University Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
US5733541A (en) 1995-04-21 1998-03-31 The Regent Of The University Of Michigan Hematopoietic cells: compositions and methods
CN1068014C (en) 1995-04-27 2001-07-04 普罗克特和甘保尔公司 Carrier substrate treated with high internal water phase inverse emulsion made with organopolysiloxane-polyoxyalkylene emulsifier
US5925567A (en) 1995-05-19 1999-07-20 T. Breeders, Inc. Selective expansion of target cell populations
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US5830708A (en) 1995-06-06 1998-11-03 Advanced Tissue Sciences, Inc. Methods for production of a naturally secreted extracellular matrix
AU6223296A (en) 1995-06-07 1996-12-30 Novartis Ag Methods for obtaining compositions enriched for hematopoieti c stem cells and antibodies for use therein
US5877299A (en) 1995-06-16 1999-03-02 Stemcell Technologies Inc. Methods for preparing enriched human hematopoietic cell preparations
US6306575B1 (en) 1995-06-16 2001-10-23 Stemcell Technologies, Inc. Methods for preparing enriched human hematopoietic cell preparations
US5654381A (en) 1995-06-16 1997-08-05 Massachusetts Institute Of Technology Functionalized polyester graft copolymers
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5858782A (en) 1995-11-13 1999-01-12 Regents Of The University Of Michigan Functional human hematopoietic cells
WO1997018298A1 (en) 1995-11-14 1997-05-22 Regents Of The University Of Minnesota Ex vivo culture of stem cells
JP3781433B2 (en) 1995-11-16 2006-05-31 ケース ウエスターン リザーブ ユニバーシティ In vitro chondrogenesis induction of human mesenchymal stem cells
WO1997019172A1 (en) 1995-11-17 1997-05-29 Asahi Kasei Kogyo Kabushiki Kaisha Differentiation-suppressive polypeptide
US5716794A (en) 1996-03-29 1998-02-10 Xybernaut Corporation Celiac antigen
EP2105138A3 (en) 1996-04-19 2013-06-05 Osiris Therapeutics, Inc. Regeneration and augmentation of bone using mesenchymal stem cells
AU2808397A (en) 1996-04-26 1997-11-19 Case Western Reserve University Skin regeneration using mesenchymal stem cells
US5919176A (en) 1996-05-14 1999-07-06 Children's Hospital Medical Center Of Northern California Apparatus and method for collecting blood from an umbilical cord
US5827740A (en) 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
US5851984A (en) 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US5916202A (en) 1996-08-30 1999-06-29 Haswell; John N. Umbilical cord blood collection
US6227202B1 (en) 1996-09-03 2001-05-08 Maulana Azad Medical College Method of organogenesis and tissue regeneration/repair using surgical techniques
US5945337A (en) 1996-10-18 1999-08-31 Quality Biological, Inc. Method for culturing CD34+ cells in a serum-free medium
US5919702A (en) 1996-10-23 1999-07-06 Advanced Tissue Science, Inc. Production of cartilage tissue using cells isolated from Wharton's jelly
US5969105A (en) 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
US6335195B1 (en) 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US6152142A (en) 1997-02-28 2000-11-28 Tseng; Scheffer C. G. Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AU8476698A (en) 1997-07-03 1999-01-25 Osiris Therapeutics, Inc. Human mesenchymal stem cells from peripheral blood
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
DE69831957T3 (en) 1997-07-14 2009-07-23 Osiris Therapeutics, Inc. HEART MUSCLES GENERATION USING MESENCHYMAL STEM CELLS
US6077708A (en) 1997-07-18 2000-06-20 Collins; Paul C. Method of determining progenitor cell content of a hematopoietic cell culture
US5879318A (en) 1997-08-18 1999-03-09 Npbi International B.V. Method of and closed system for collecting and processing umbilical cord blood
AU9127098A (en) 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
US6059968A (en) 1998-01-20 2000-05-09 Baxter International Inc. Systems for processing and storing placenta/umbilical cord blood
US6291240B1 (en) 1998-01-29 2001-09-18 Advanced Tissue Sciences, Inc. Cells or tissues with increased protein factors and methods of making and using same
ES2237089T3 (en) 1998-03-13 2005-07-16 Osiris Therapeutics, Inc. USES FOR NON-AUTOMATIC HUMAN MESENQUIMATE MOTHER CELLS
DK1066052T3 (en) 1998-03-18 2006-06-12 Osiris Therapeutics Inc Mesenchymal stem cells for the prevention and treatment of immune responses in transplants
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
ATE246938T1 (en) 1998-04-03 2003-08-15 Osiris Therapeutics Inc APPLICATION OF MESENCHYMAL STEM CELLS AS IMMUNOSUPPRESSANTS
US6300314B1 (en) 1998-05-04 2001-10-09 Point Therapeutics, Inc. Hematopoietic stimulation
US6835377B2 (en) 1998-05-13 2004-12-28 Osiris Therapeutics, Inc. Osteoarthritis cartilage regeneration
AU4094099A (en) 1998-05-22 1999-12-13 Osiris Therapeutics, Inc. Production of megakaryocytes by co-culturing human mesenchymal stem cells with cd34+ cells
ES2292245T3 (en) 1998-05-29 2008-03-01 Osiris Therapeutics, Inc. MESENCHIMATIC MOTHER CELLS CD45 + AND / OR FIBROBLASTO + HUMANAS.
EP1108011A2 (en) 1998-06-08 2001-06-20 Osiris Therapeutics, Inc. In vitro maintenance of hematopoietic stem cells
ATE375799T1 (en) 1998-06-08 2007-11-15 Osiris Therapeutics Inc REGULATION OF HEMATOPOIETIC STEM CELL DIFFERENTIATION BY USING HUMAN MESENCHYMAL STEM CELLS
US6713245B2 (en) 1998-07-06 2004-03-30 Diacrin, Inc. Methods for storing neural cells such that they are suitable for transplantation
PT1100488E (en) 1998-07-28 2003-09-30 Synthes Ag USE OF CREATINE COMPOUNDS FOR TREATMENT OF BONE AND CARTILAGE CELLS AND TISSUES
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
JP3517359B2 (en) 1998-09-14 2004-04-12 テルモ株式会社 Cell separation / collection apparatus and cell separation / collection method
CA2345397A1 (en) 1998-09-23 2000-03-30 Mount Sinai Hospital Trophoblast cell preparations
EP1129176A4 (en) 1998-11-09 2002-10-30 Es Cell Int Pte Ltd Embryonic stem cells
US6548299B1 (en) 1999-11-12 2003-04-15 Mark J. Pykett Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices
CA2351889A1 (en) 1998-11-12 2000-05-18 Cell Science Therapeutics, Inc. Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices
US6184035B1 (en) 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
US6328765B1 (en) 1998-12-03 2001-12-11 Gore Enterprise Holdings, Inc. Methods and articles for regenerating living tissue
CN1182882C (en) 1998-12-24 2005-01-05 生物安全股份有限公司 Blood separation system especially for concentrating hematopoietic stem cells
US20030007954A1 (en) 1999-04-12 2003-01-09 Gail K. Naughton Methods for using a three-dimensional stromal tissue to promote angiogenesis
DE60034045T2 (en) 1999-04-16 2007-11-22 WM. Marsh Rice University, Houston Biodegradable polypropylene fumarate networks crosslinked with polypropylene fumarate diacrylate macromers
IN191359B (en) 1999-04-20 2003-11-29 Nat Inst Immunology
AU4860900A (en) 1999-06-02 2000-12-18 Lifebank Services, L.L.C. Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells
US6355699B1 (en) 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
US6333029B1 (en) 1999-06-30 2001-12-25 Ethicon, Inc. Porous tissue scaffoldings for the repair of regeneration of tissue
WO2002064748A2 (en) 2001-02-14 2002-08-22 Furcht Leo T Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US8075881B2 (en) 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US6239157B1 (en) 1999-09-10 2001-05-29 Osiris Therapeutics, Inc. Inhibition of osteoclastogenesis
US6685936B2 (en) 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US6280718B1 (en) 1999-11-08 2001-08-28 Wisconsin Alumni Reasearch Foundation Hematopoietic differentiation of human pluripotent embryonic stem cells
US7405078B2 (en) 2000-03-16 2008-07-29 Cellseed Inc. Bed material for cell culture, method for co-culture of cell and co-cultured cell sheet obtainable therefrom
US20010038836A1 (en) 2000-04-04 2001-11-08 Matthew During Application of myeloid-origin cells to the nervous system
ES2267778T3 (en) 2000-06-06 2007-03-16 Glaxo Group Limited COMPOSITION FOR THE TREATMENT OF CANCER, CONTAINING AN ANTI-NEOPLASTIC AGENT AND A PDE4 INHIBITOR.
CA2430669C (en) 2000-11-30 2011-06-14 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
ES2522890T3 (en) 2000-12-06 2014-11-19 Anthrogenesis Corporation Method to collect placental stem cells
US20080152629A1 (en) 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
EP3246396B1 (en) 2001-02-14 2020-01-29 Celularity, Inc. Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
IL157350A0 (en) 2001-02-14 2004-02-19 Anthrogenesis Corp Post-partum mammalian placenta, its use and placental stem cells therefrom
US20020132343A1 (en) 2001-03-19 2002-09-19 Clark Lum System and method for delivering umbilical cord-derived tissue-matched stem cells for transplantation
US20030022358A1 (en) 2001-05-29 2003-01-30 Hall Jane H. Growth of filterable organisms that require non-diffusable media components
CA2396536A1 (en) 2001-08-10 2003-02-10 Saiko Uchida Human stem cells originated from human amniotic mesenchymal cell layer
DE10139783C1 (en) 2001-08-14 2003-04-17 Transtissue Technologies Gmbh Cell compositions for the treatment of osteoarthritis, and methods for their production
EP1288293A1 (en) 2001-08-30 2003-03-05 Norio Sakuragawa Human neural stem cells originated from human amniotic mesenchymal cell layer
CN1195055C (en) 2001-09-06 2005-03-30 周胜利 Method for establishing hematopoietic stem cells bank by extracting hematopoietic cells from placenta tissues
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
WO2003042405A2 (en) 2001-11-15 2003-05-22 Children's Medical Center Corporation Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
JP3728750B2 (en) 2001-11-22 2005-12-21 ニプロ株式会社 Cultured skin and method for producing the same
US7799324B2 (en) 2001-12-07 2010-09-21 Geron Corporation Using undifferentiated embryonic stem cells to control the immune system
JP3934539B2 (en) 2001-12-12 2007-06-20 独立行政法人科学技術振興機構 Adult or postnatal tissue progenitor cells derived from placenta
WO2003061591A2 (en) 2002-01-22 2003-07-31 Advanced Cell Technology, Inc. Stem cell-derived endothelial cells modified to disrupt tumor angiogenesis
NZ534643A (en) 2002-02-13 2010-06-25 Anthrogenesis Corp Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
US7736892B2 (en) 2002-02-25 2010-06-15 Kansas State University Research Foundation Cultures, products and methods using umbilical cord matrix cells
US20030161818A1 (en) 2002-02-25 2003-08-28 Kansas State University Research Foundation Cultures, products and methods using stem cells
KR20050013531A (en) 2002-03-15 2005-02-04 디파트먼트 오브 베테랑스 어페어스 오피스 오브 더 제네럴 카운셀 (024) Methods and Compositions Using Cellular Asialodeterminants and Glycoconjugates for Targeting Cells to Tissues and Organs
US20030187515A1 (en) 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
ZA200408369B (en) 2002-04-12 2006-11-29 Celgene Corp Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
KR20050000400A (en) 2002-04-12 2005-01-03 셀진 코포레이션 Modulation of stem and progenitor cell differentiation, assays, and uses thereof
EP1497435A4 (en) 2002-04-19 2005-07-27 Univ Pittsburgh PLACENTAL STEM CELLS AND USES
US20040161419A1 (en) 2002-04-19 2004-08-19 Strom Stephen C. Placental stem cells and uses thereof
EP1525308A4 (en) 2002-05-30 2006-11-02 Celgene Corp Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes
US7422736B2 (en) 2002-07-26 2008-09-09 Food Industry Research And Development Institute Somatic pluripotent cells
BR0305721A (en) 2002-07-31 2004-09-28 Saint Laurent Parfums Human stem cell, cell population, process for obtaining stem cells, for the production of differentiated cells of the mesodermal lineage, for selection that allows to identify agents susceptible to present lipolytic activity and insulin-sensitizing activity, use of a cell , stem cell utilization, pharmaceutical composition, human cell, multipotent human cell population
EP1535994A4 (en) 2002-08-23 2005-12-07 Srl Inc HUMAN BONE STEM CELLS
US20040062753A1 (en) 2002-09-27 2004-04-01 Alireza Rezania Composite scaffolds seeded with mammalian cells
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
CA2505534A1 (en) 2002-11-26 2004-06-10 Anthrogenesis Corporation Cytotherapeutics, cytotherapeutic units and methods for treatments using them
DE602004028803D1 (en) 2003-02-11 2010-10-07 John E Davies PRECURSOR CELLS FROM THE WHARTON SULCE OF HUMAN NECK LOCKS
JP2006517975A (en) 2003-02-13 2006-08-03 アンスロジェネシス コーポレーション Use of umbilical cord blood to treat an individual suffering from a disease, disorder or condition
WO2004087896A2 (en) 2003-03-31 2004-10-14 Pfizer Products Inc. Hepatocyte differentiation of stem cells
CN1548529A (en) 2003-05-09 2004-11-24 中国人民解放军军事医学科学院基础医 A method for isolating human placental mesenchymal stem cells
US7255729B2 (en) 2003-05-30 2007-08-14 Noritake Co., Limited Porous cylindrical-body module, structure for supporting porous cylindrical bodies, and method for fastening a supporting member
WO2005001079A2 (en) 2003-06-27 2005-01-06 Ethicon, Incorporated Soft tissue repair and regeneration using postpartum-derived cells
US7875272B2 (en) * 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US7569385B2 (en) 2003-08-14 2009-08-04 The Regents Of The University Of California Multipotent amniotic fetal stem cells
US20050089513A1 (en) 2003-10-28 2005-04-28 Norio Sakuragawa Side population cells originated from human amnion and their uses
WO2005047491A2 (en) 2003-11-10 2005-05-26 Amgen Inc. Methods of using g-csf mobilized c-kit+cells in the production of embryoid body-like cell clusters for tissue repair and in the treatment of cardiac myopathy
KR100560340B1 (en) 2003-11-11 2006-03-14 한훈 Isolation and Culture Method of Mesenchymal Stem Cells from Umbilical Cord Blood
JP2005151907A (en) 2003-11-27 2005-06-16 Shigeo Saito Human stem cell derived from placenta or amnion and method for establishing the same and method for differentiation-induction to organ
TWI338714B (en) 2003-12-02 2011-03-11 Cathay General Hospital Method of isolation and enrichment of mesenchymal stem cells from amniotic fluid
CN101966183A (en) 2003-12-02 2011-02-09 细胞基因公司 Methods and compositions for the treatment and management of hemoglobinopathy and anemia
US20050176139A1 (en) 2004-01-12 2005-08-11 Yao-Chang Chen Placental stem cell and methods thereof
US20050266391A1 (en) 2004-01-15 2005-12-01 Bennett Brydon L Methods for preserving tissue
CA2564679C (en) 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
JP2007531116A (en) 2004-03-26 2007-11-01 セルジーン・コーポレーション System and method for providing a stem cell bank
WO2005105992A1 (en) 2004-04-21 2005-11-10 New York Eye & Ear Infirmary Chondrocyte culture formulations
JP2006006249A (en) 2004-06-28 2006-01-12 Hiroshima Univ Method for culturing amnion-derived cells and use thereof
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
WO2006015214A2 (en) 2004-07-29 2006-02-09 Steenblock Research Institute, Inc. Umbilical cord stem cell composition & method of treating neurological diseases
BRPI0514387B8 (en) 2004-08-16 2021-05-25 Cellresearch Corp Pte Ltd method to isolate epithelial or mesenchymal/progenitor stem cells from the amniotic membrane of the umbilical cord, in vitro method for culturing mesenchymal/progenitor stem cells, pharmaceutical composition and use of an epithelial or mesenchymal/progenitor stem cell
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
US7909806B2 (en) 2004-09-23 2011-03-22 Anthrogenesis Corporation Cord blood and placenta collection kit
US8039258B2 (en) 2004-09-28 2011-10-18 Ethicon, Inc. Tissue-engineering scaffolds containing self-assembled-peptide hydrogels
US20060171930A1 (en) 2004-12-21 2006-08-03 Agnieszka Seyda Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same
US20060166361A1 (en) 2004-12-21 2006-07-27 Agnieszka Seyda Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
AU2005322068B2 (en) 2004-12-23 2011-09-01 Ethicon Incorporated Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
PL1831356T3 (en) 2004-12-23 2017-07-31 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US20070041943A1 (en) 2004-12-29 2007-02-22 Children's Hospital Research Expression of virus entry inhibitors and recombinant AAV thereof
US9056093B2 (en) 2005-01-07 2015-06-16 Wake Forest University Health Sciences Regeneration of pancreatic islets by amniotic fluid stem cell therapy
WO2006091766A2 (en) 2005-02-24 2006-08-31 Jau-Nan Lee Human trophoblast stem cells and use thereof
US20060222634A1 (en) 2005-03-31 2006-10-05 Clarke Diana L Amnion-derived cell compositions, methods of making and uses thereof
EP1871873A1 (en) 2005-04-16 2008-01-02 Axordia Limited Cytotrophoblast stem cell
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
WO2006135843A2 (en) 2005-06-10 2006-12-21 Celgene Corporation Human placental collagen compositions, processes for their preparation, methods of their use and kits comprising the compositions
BRPI0612121A2 (en) 2005-06-30 2016-09-06 Anthrogenesis Corp method of repairing a tympanic membrane that has a deformity, and collagen
US7928280B2 (en) 2005-07-13 2011-04-19 Anthrogenesis Corporation Treatment of leg ulcers using placenta derived collagen biofabric
WO2007009061A2 (en) 2005-07-13 2007-01-18 Anthrogenesis Corporation Ocular plug formed from placenta derived collagen biofabric
WO2007011693A2 (en) 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
WO2007024441A2 (en) 2005-08-19 2007-03-01 Bio Regenerate, Inc. Compositions of cells enriched for combinations of various stem and progenitor cell populations, methods of use thereof and methods of private banking thereof
ES2452595T3 (en) 2005-10-13 2014-04-02 Anthrogenesis Corporation Immunomodulation using placental stem cells
NZ567334A (en) 2005-10-13 2012-08-31 Anthrogenesis Corp Production of oligodendrocytes from placenta-derived stem cells
CN100344757C (en) 2005-10-18 2007-10-24 天津昂赛细胞基因工程有限公司 Human placenta, umbilical cord mesenchyma stemcell stock and its construction method
ES2642844T3 (en) 2005-12-16 2017-11-20 DePuy Synthes Products, Inc. Compositions and methods to inhibit an adverse immune response in histocompatibility transplantation that do not match
US8741638B2 (en) 2005-12-19 2014-06-03 DePuy Synthes Products, LLC In vitro expansion of postpartum-derived cells in roller bottles
CA2634820C (en) 2005-12-22 2021-05-25 Jane Ennis Viable cells from frozen umbilical cord tissue
AU2006330409B2 (en) 2005-12-28 2012-07-19 Ethicon, Incorporated Treatment of peripheral vascular disease using postpartum-derived cells
EP2412801A1 (en) 2005-12-29 2012-02-01 Anthrogenesis Corporation Co-Culture of placental stem cells and stem cells from a second source
ES2549111T3 (en) 2005-12-29 2015-10-23 Anthrogenesis Corporation Placental stem cell populations
EP1974013A2 (en) 2005-12-29 2008-10-01 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
US20070253931A1 (en) 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
US9944900B2 (en) 2006-01-18 2018-04-17 Hemacell Perfusion Pulsatile perfusion extraction method for non-embryonic pluripotent stem cells
CN104027359A (en) 2006-01-23 2014-09-10 阿特西斯公司 MAPC Therapeutics Without Adjunctive Immunosuppressive Treatment
ZA200810412B (en) 2006-06-09 2010-03-31 Anthrogenesis Corp Placental niche and use thereof to culture stem cells
US20070287176A1 (en) 2006-06-13 2007-12-13 Alireza Rezania Chorionic villus derived cells
US7993918B2 (en) * 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
US8105634B2 (en) 2006-08-15 2012-01-31 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
WO2008042441A1 (en) 2006-10-03 2008-04-10 Anthrogenesis Corporation Use of umbilical cord biomaterial for ocular surgery
WO2008060377A2 (en) 2006-10-04 2008-05-22 Anthrogenesis Corporation Placental or umbilical cord tissue compositions
EP2076279B1 (en) 2006-10-06 2014-08-27 Anthrogenesis Corporation Native (telopeptide) placental collagen compositions
CA2667359C (en) 2006-10-23 2014-07-22 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
EP2089511B1 (en) 2006-11-13 2014-09-17 DePuy Synthes Products, LLC In vitro expansion of postpartum-derived cells using microcarriers
WO2008100497A1 (en) 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations
DK2120977T3 (en) 2007-02-12 2013-08-12 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
US20100172830A1 (en) 2007-03-29 2010-07-08 Cellx Inc. Extraembryonic Tissue cells and method of use thereof
RU2010109698A (en) * 2007-09-19 2011-09-27 Плуристем Лтд. (Il) ADHESIVE CELLS OF FATTY TISSUE OR PLACENTA AND THEIR USE FOR MEDICAL PURPOSES
US20090104164A1 (en) * 2007-09-26 2009-04-23 Celgene Cellular Therapeutics Angiogenic cells from human placental perfusate
CN101878034B (en) 2007-09-28 2013-11-20 细胞基因细胞疗法公司 Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
AU2008325142A1 (en) 2007-11-07 2009-05-14 Anthrogenesis Corporation Use of umbilical cord blood in the treatment of premature birth complications
KR20200143506A (en) 2008-08-20 2020-12-23 안트로제네시스 코포레이션 Treatment of stroke using isolated placental cells
ES2612469T3 (en) 2008-08-20 2017-05-17 Anthrogenesis Corporation Improved cell composition and methods of making it
CA2734446C (en) 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
MX2011002328A (en) * 2008-09-02 2011-05-19 Pluristem Ltd Adherent cells from placenta tissue and use thereof in therapy.
JP5869342B2 (en) 2008-11-19 2016-02-24 アンスロジェネシス コーポレーション Amnion-derived adherent cells
WO2010060031A1 (en) 2008-11-21 2010-05-27 Anthrogenesis Corporation Treatment of diseases, disorders or conditions of the lung using placental cells
WO2010141654A1 (en) 2009-06-05 2010-12-09 Anthrogenesis Corporation Improved method of collecting placental cells
MX353489B (en) 2009-07-02 2018-01-16 Anthrogenesis Corp Method of producing erythrocytes without feeder cells.
WO2011094181A1 (en) 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
US20110280849A1 (en) 2010-03-26 2011-11-17 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
LT2556145T (en) 2010-04-07 2016-11-10 Anthrogenesis Corporation Angiogenesis using placental stem cells
KR20130092394A (en) 2010-04-08 2013-08-20 안트로제네시스 코포레이션 Treatment of sarcoidosis using placental stem cells
JP5996533B2 (en) 2010-07-13 2016-09-21 アントフロゲネシス コーポレーション How to generate natural killer cells
US20120171161A1 (en) 2010-12-30 2012-07-05 Sascha Abramson Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
EP2658556A4 (en) 2010-12-30 2015-03-04 Anthrogenesis Corp METHODS OF CRYOPRESERVATION AND ENCAPSULATION OF CELLS
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
WO2012166844A2 (en) 2011-06-01 2012-12-06 Anthrogenesis Corporation Treatment of pain using placental stem cells

Also Published As

Publication number Publication date
CN102933703A (en) 2013-02-13
ZA201606733B (en) 2019-12-18
JP6097684B2 (en) 2017-03-15
EP3088512A1 (en) 2016-11-02
ES2602474T3 (en) 2017-02-21
AU2011237747B2 (en) 2015-07-23
PT2556145T (en) 2016-10-25
KR20220015489A (en) 2022-02-08
RS55287B1 (en) 2017-03-31
SMT201600377B (en) 2017-01-10
PL2556145T3 (en) 2017-02-28
MX2012011542A (en) 2013-05-30
CA2795518C (en) 2020-03-24
EP2556145B1 (en) 2016-07-20
AR081166A1 (en) 2012-07-04
LT2556145T (en) 2016-11-10
US9254302B2 (en) 2016-02-09
MX347451B (en) 2017-04-27
KR20230054905A (en) 2023-04-25
HUE029144T2 (en) 2017-02-28
US20160106784A1 (en) 2016-04-21
KR20190076060A (en) 2019-07-01
JP2016192966A (en) 2016-11-17
TW201902496A (en) 2019-01-16
CA2795518A1 (en) 2011-10-13
TWI578993B (en) 2017-04-21
JP2013523152A (en) 2013-06-17
KR20210029310A (en) 2021-03-15
AU2011237747A1 (en) 2012-11-01
NZ630009A (en) 2016-05-27
AR111656A2 (en) 2019-08-07
TW201703777A (en) 2017-02-01
TW202122099A (en) 2021-06-16
JP2021006041A (en) 2021-01-21
US20180071343A1 (en) 2018-03-15
TW201138791A (en) 2011-11-16
EP2556145A1 (en) 2013-02-13
TWI756797B (en) 2022-03-01
DK3088512T3 (en) 2020-03-16
IL250234A0 (en) 2017-03-30
SI2556145T1 (en) 2017-01-31
WO2011127117A1 (en) 2011-10-13
KR101993254B1 (en) 2019-06-26
IL250234B (en) 2020-08-31
JP2022160449A (en) 2022-10-19
IL222321A0 (en) 2012-12-31
MX2019001414A (en) 2019-07-04
DK2556145T3 (en) 2016-11-07
EP2556145A4 (en) 2013-11-13
KR20200047797A (en) 2020-05-07
IL250234B2 (en) 2023-10-01
TW202011974A (en) 2020-04-01
KR20130100053A (en) 2013-09-09
MX337172B (en) 2016-02-16
IL222321A (en) 2017-02-28
KR20240096688A (en) 2024-06-26
US20110250182A1 (en) 2011-10-13
HRP20161350T1 (en) 2016-12-16
CN107699541A (en) 2018-02-16
CY1118105T1 (en) 2017-06-28
EP3088512B1 (en) 2019-12-11
JP2018161133A (en) 2018-10-18

Similar Documents

Publication Publication Date Title
NZ602808A (en) Angiogenesis using placental stem cells
NZ602798A (en) Treatment of sarcoidosis using placental stem cells
WO2014028668A3 (en) Stem cell enhancing therapeutics
PH12015501558B1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
WO2013177133A3 (en) Generation of human ips cells by a synthetic self- replicative rna
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
AU2018256561A1 (en) Aminosteroids for the treatment of a PTP1B associated disease
PH12015500954A1 (en) Device for extracorporeal blood treatment
CO7200258A2 (en) Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium compositions for the treatment of hyperkalemia
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
MX362271B (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof.
SG10201803778PA (en) Treatment for rheumatoid arthritis
WO2012065110A3 (en) S-protected cysteine analogs and related compounds
CR20110552A (en) TREATMENT OF INSULIN RESISTANT DISORDERS
WO2012131001A3 (en) Cushion for patient interface
GB2496795A (en) A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
MX2016001195A (en) Methods for improving asthma symptoms using benralizumab.
MX2015012580A (en) The use of sdf-1 to mitigate scar formation.
UA114486C2 (en) APPLICATION OF 4-AMINOPYRIDINE IN THE TREATMENT OF MULTIPLE-SENSOR-MOTOR DISORDER TREATMENT
MX2012015112A (en) Use of a2b adenosine receptor antagonists for treating pulmonary hypertension.
WO2014049580A3 (en) Assay to monitor autophagy, a method and kit thereof
MY203748A (en) Treatment of diabetic peripheral neuropathy using placental cells
Matsunaga et al. Sugiura H, Kawabata H, Ichikawa T, Koarai A, Yanagisawa S, Kikuchi T, Minakata Y

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 3052460, ANTHROGENESIS CORPORATION, 33 TECHNOLOGY DRIVE, WARREN NJ 07059, US

Effective date: 20130513

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2016 BY COMPUTER PACKAGES INC

Effective date: 20150331

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2017 BY COMPUTER PACKAGES INC

Effective date: 20160318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180320

ASS Change of ownership

Owner name: CELULARITY, INC., US

Effective date: 20180924

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190319

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2023 BY COMPUTER PACKAGES INC

Effective date: 20220317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2024 BY COMPUTER PACKAGES INC

Effective date: 20230317

LAPS Patent lapsed